Pliant Therapeutics, Inc.
(NASDAQ : PLRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 1.46%243.821.3%$795.90m
IMMUImmunomedics, Inc. 0.07%85.3611.0%$697.18m
MRNAModerna, Inc. 6.60%69.470.0%$666.49m
NVAXNovavax, Inc. 10.86%113.5696.5%$629.01m
ILMNIllumina, Inc. 4.74%299.893.5%$582.79m
GILDGilead Sciences, Inc. 0.00%62.251.0%$574.11m
REGNRegeneron Pharmaceuticals, Inc. 2.98%574.062.7%$443.39m
VRTXVertex Pharmaceuticals, Inc. 1.92%268.181.9%$340.86m
BIIBBiogen, Inc. 1.20%273.281.6%$334.97m
ALXNAlexion Pharmaceuticals, Inc. 2.15%114.432.0%$285.22m
EXASEXACT Sciences Corp. 3.60%97.7020.7%$257.29m
SRNESorrento Therapeutics, Inc. 4.84%9.641.5%$240.99m
VXRTVaxart, Inc. 7.40%7.400.0%$213.88m
SGENSeattle Genetics, Inc. 3.08%184.956.0%$212.14m
MNTAMomenta Pharmaceuticals, Inc. 0.02%52.403.0%$193.58m

Company Profile

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.